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Abstract
Purpose Primary breast and prostate cancers can be cured, but metastatic disease cannot. Identifying cell factors that predict 
metastatic potential could guide both prognosis and treatment.
Methods We used Cell-SELEX to screen an RNA aptamer library for differential binding to prostate cancer cell lines with 
high vs. low metastatic potential. Mass spectroscopy, immunoblot, and immunohistochemistry were used to identify and 
validate aptamer targets. Aptamer properties were tested in vitro, in xenograft models, and in clinical biopsies. Gene expres-
sion datasets were queried for target associations in cancer.
Results We identified a novel aptamer (Apt63) that binds to the beta subunit of  F1Fo ATP synthase (ATP5B), present on the 
plasma membrane of certain normal and cancer cells. Apt63 bound to plasma membranes of multiple aggressive breast and 
prostate cell lines, but not to normal breast and prostate epithelial cells, and weakly or not at all to non-metastasizing cancer 
cells; binding led to rapid cell death. A single intravenous injection of Apt63 induced rapid, tumor cell-selective binding and 
cytotoxicity in MDA-MB-231 xenograft tumors, associated with endonuclease G nuclear translocation and DNA fragmen-
tation. Apt63 was not toxic to non-transformed epithelial cells in vitro or adjacent normal tissue in vivo. In breast cancer 
tissue arrays, plasma membrane staining with Apt63 correlated with tumor stage (p < 0.0001, n = 416) and was independent 
of other cancer markers. Across multiple datasets, ATP5B expression was significantly increased relative to normal tissue, 
and negatively correlated with metastasis-free (p = 0.0063, 0.00039, respectively) and overall (p = 0.050, 0.0198) survival.
Conclusion Ecto-ATP5B binding by Apt63 may disrupt an essential survival mechanism in a subset of tumors with high 
metastatic potential, and defines a novel category of cancers with potential vulnerability to ATP5B-targeted therapy. Apt63 
is a unique tool for elucidating the function of surface ATP synthase, and potentially for predicting and treating metastatic 
breast and prostate cancer.
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Introduction
Localized prostate and breast cancers are highly curable, but 
once metastasized to remote organs, these cancers are inevi-
tably lethal. Consequently, an important goal of treatment is 
to identify and exploit specific vulnerabilities of the meta-
static cell. Another key aim is to predict which tumors are 
at high risk of metastasis, allowing potentially toxic therapy 
to be tailored to those most likely to benefit. These goals 
have been aided by an improved understanding of cancer 
cell genetic drift during tumor progression, which allows 
certain cells to acquire independence from supportive factors 
in the tissue of origin, to migrate into the vasculature, and 
to survive and grow at foreign sites such as liver and bone. 
In addition to genetic drivers of the metastatic phenotype 
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[1–5], epigenetic and protein-level changes have been found 
to establish tumor cell aggressiveness, including episomal 
transfer of microRNAs to and from adjacent normal cells, 
reprogramming of the tumor or stroma by factors released 
from tumor-infiltrating lymphocytes, and alterations in 
metabolism brought about by tumor hypoxia [6–8]. Energy 
production from carbon sources is frequently deranged in 
cancer, and may be associated with changes in the epigenetic 
state of the cell that promote cell-autonomous increases in 
tumor aggression (reviewed in [8]). A thorough search for 
metastasis-promoting changes in the cancer cell thus neces-
sarily extends to exploration of protein content, function, 
and location.
In this study, we used an unsupervised method: differ-
ential Cell-SELEX (Systematic Evolution of Ligands by 
EXponential enrichment), to search for proteins distinguish-
ing metastatic from non-metastatic subclones of a single 
parental prostate cancer cell line, LNCaP. Owing to their 
unique, sequence-specific tertiary structure, single-stranded 
nucleic acids (either DNA or RNA) can bind to individ-
ual proteins with high specificity and affinity, comparable 
to those of antibodies. These oligonucleotides, known as 
aptamers, can be modified for stability in biological fluids, 
labeled with fluorescent tags, fused to other molecules, and 
delivered in vivo without inciting an immune response [9]. 
Cell-SELEX uses live cells to select aptamers that recognize 
cellular proteins in their native and functional state. Dif-
ferential Cell-SELEX applies the same method to identify 
aptamers that discriminate between two cell types. The abil-
ity to screen large numbers (> 240) of sequences increases 
the likelihood of identifying rare or unique surface marker 
differences.
Here, we report the identification of a novel RNA aptamer 
(Apt63) that recognizes a plasma membrane feature that is 
commonly expressed by multiple aggressive prostate and 
breast cancer cell lines and tumors, but that exhibits low 
expression or is absent in non-transformed cells and nor-
mal tissues. We demonstrate that the aptamer target is the 
beta subunit of  F1Fo ATP synthase (ATP5B). This protein is 
a catalytic component of the final enzyme in cellular ATP 
production by oxidative phosphorylation, and is located 
on the inner mitochondrial membrane. ATP5B and other 
components of the  F1Fo ATP synthase complex have previ-
ously been identified on the plasma membrane of certain 
cell and tumor types, where it is referred to as “ecto-ATP 
synthase”; several studies have shown that the complex is 
catalytically active in extracellular ATP production [10, 
11]. Various roles have been established for this activity in 
a few normal cell types, and particularly in angiogenesis, 
but its significance and function in cancer remain uncer-
tain. Ecto-ATP synthase acts as a ligand for angiostatin and 
transduces some of its anti-proliferative and anti-angiogenic 
effects [12]. Binding to ecto-ATP synthase by angiostatin, 
membrane-impermeable small molecules and monoclonal 
antibodies against the ATP5 beta subunit have been shown 
to promote cell death in a wide range of susceptible cell 
types, including HeLa, Leishmania, and plant cells ([13] 
and citations therein; [14–16]). Several studies have linked 
expression of surface ATP synthase to more-aggressive and 
later-stage cancer [17, 18], suggesting that the activity of 
this complex on the cell surface may support the survival 
of these aggressive cells during the transition to metastasis. 
In this study, we show that Apt63 distinguishes aggressive 
breast and prostate cancer cell lines from less-aggressive 
congenic lines, and from non-transformed cells, both human 
and murine. In vivo, Apt63 binds selectively to ecto-ATP5B-
expressing tumors and not to normal adjacent tissue. Func-
tionally, binding of Apt63 to the plasma membrane exerts 
selective tumor cell killing by inducing translocation of 
endonuclease G from mitochondria to nucleus, DNA frag-
mentation, and apoptosis. We show that that Apt63 plasma 
membrane binding in clinical tissue biopsies is strongly cor-
related with advanced tumor stage, and as a corollary, that 
ATP5B expression in primary tumors is predictive of poor 
metastasis-free and overall survival. We propose that Apt63 
may be useful in early recognition and treatment of a novel 
subset of highly aggressive primary breast and prostate can-
cers, defined by surface expression of ATP5B.
Materials and methods
Cell lines and cell culture
Human prostate cancer cell lines used in the Cell-SELEX 
screen were obtained from Dr. Curtis Pettaway [19]. Human 
prostate cancer cells (PC-3, PC3-ML, RWPE-1) were gen-
erously provided by Dr. Kerry Burnstein (University of 
Miami), and human breast cancer cell lines (MDA-MB-231, 
MDA-MB-436, MCF7, MCF10) were obtained from ATCC 
(Manassas, VA), Murine breast cancer cells lines (4T1, 
67NR, E0771, E0771.LMB) were the gift of Dr. Barry 
Hudson (University of Miami). Dissociated primary tumor 
lines DT28 and DT22 were the generous gift of Dr. D. El-
Ashry (University of Minnesota) [20]. All cell lines were 
maintained using the suppliers’ protocols and maintained 
in 37 °C, 5%  CO2 tissue culture incubators. All cell lines 
were routinely tested for mycoplasma using the MycoAlert 
Mycoplasma Detection Kit (Lonza, Walkersville, MD, USA) 
and an established PCR protocol [21].
Differential Cell‑SELEX
The pool of RNA aptamers used for Cell-SELEX was 
obtained from a cDNA library with the general template: 
TCT CGG ATC CTC AGC GAG TCG TCT G-(N40)-CCG 
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CAT CGT CCT CCC TA (where N40 represents 40 random 
nucleotides). The cDNA library was amplified by PCR and 
transcribed in vitro using a Durascribe T7 RNA synthesis kit 
(Lucigene, USA) with nuclease-stable 2ʹ-F-dCTP and 2ʹ-F-
dUTP as previously described [22]. The aptamer library was 
purified using an RNeasy kit (Qiagen). Both parental and 
LNCaP-Pro5 (Pro5) cells were used for negative selection, 
and LNCaP-LN3 (LN3) for positive selection. Each Cell-
SELEX cycle consists two rounds of selection, negative and 
positive. Parental LNCaP cells were used in the first three 
selection cycles and Pro5 cells in cycles 4–11. At the begin-
ning of each cycle, 1 µg of the aptamer library was added to 
450 µL of PBS containing 0.5 mM MgCl2 and 1 mM  CaCl2 
(binding buffer) and RNA was refolded by heating 5 min at 
67 °C and cooling at room temperature (RT) for 10 min. All 
cells used in Cell-SELEX were grown in 75T culture flasks 
with filtered cups (ThermoFisher Scientific). At 75% conflu-
ency, cells were briefly washed with PBS and dissociated 
from the flask by incubation with 3 ml of Trypsin–EDTA 
(0.25%) without phenol red (ThermoFisher Scientific) in 
RT for 3 min. 10 ml of growing media was added to halt 
Trypsin–EDTA reaction. Detached cells were collected into 
15 ml conical tubes (Falcon) and centrifuged for 5 min in a 
4 °C tabletop centrifuge (Eppendorf) at 600×g. Cell pellets 
were resuspended in 5 ml of binding buffer and counted. 
2 × 105 Pro5 cells were separated into fresh tubes and cen-
trifuged in tabletop centrifuge for 5 min at RT; the cell pellet 
was then resuspended with the aptamer library and incu-
bated for 10 min at RT on a circular rotator to continuously 
agitate the cells. Cells were again centrifuged for 5 min at 
RT, and the supernatant, containing aptamers not bound to 
the negative selector, was collected and filtered by passing 
through 0.2 µm Pall Acrodisc® Sterile Syringe Filters with 
Supor® Membrane (Pall Laboratory). In the positive selec-
tion step, 0.5 × 105 LN3 cells were first incubated for 10 min 
at RT with 0.1 mg/ml of yeast tRNA (Sigma) to reduce non-
specific RNA binding, then LN3 cells were washed with 
binding buffer, centrifuged, and the cell pellet resuspended 
with the filtered supernatant from the negative selection. 
LN3 cells were incubated for 10 min on a rotator at RT, 
followed by isolation of total RNA (including bound aptam-
ers) using Trizol reagent (Invitrogen). RNA aptamers were 
transcribed from total RNA using an aptamer-specific for-
ward primer and a SuperScript® III Reverse Transcriptase 
reaction (Invitrogen), and amplified from first strand cDNA 
by standard PCR (95 °C, 5′, 3 × (94 °C 30″, 52 °C 20″, 72 °C 
25″), 15 × (94 °C 30″, 54 °C 20″, 72 °C 25″), 72 °C 5). RNA 
sequences were transcribed from the resulting cDNA pool 
using a Durascribe T7 kit as detailed above, and entered 
into the next Cell-SELEX cycle. RNA aptamer pools were 
sampled at cycles 1, 4, and 11. After cycle 11, aptamer pools 
were sequenced, aligned, and analyzed to select candidates 
for further study as previously described [22, 23].
Generation of aptamers and scrambled sequences 
for in vitro and in vivo experiments
Selected aptamers and scrambled oligomers were synthe-
sized by Integrated DNA Technologies (IDT, USA) and 
used as templates for amplification by PCR (95 °C, 5′, 
3 × (94 °C 30″, 52 °C 20″, 72 °C 25″), 15 × (94 °C 30″, 
54 °C 20″, 72 °C 25″), 72 °C 5′) with the universal for-
ward primer 5′-GGG GGA ATT CTA ATA CGA CTC 
ACT ATA GGG AGG ACG ATG CGG-3, and the reverse 
primer 5′-TCT CGG ATC CTC AGC GAG TCG TC-3′ 
(oligomer sequences are listed in Online Resource 1). 
RNA sequences were then transcribed by Durascribe T7 
kit (Lucigene, USA) following the manufacturer’s proto-
col. RNA aptamers and scrambled sequences were labeled 
for in vitro experiments using Silencer™ siRNA Labe-
ling Kit with Cy™3 dye (Thermo Fisher Scientific) and 
for in vivo experiments using Ulysis Alexa Fluor™ 647 
Nucleic Acid Labeling Kit (Thermo Fisher Scientific) fol-
lowing the manufacturer’s recommended protocols.
Fluorescence microscopy for aptamer imaging
Cells were seeded into 35 mm glass bottom dishes (Mat-
Tek Corporation, Ashland, MA) at a density of 0.3 × 106 
cells per dish, and allowed to grow for 48 h to 60–75% 
confluence. Cy3-labeled aptamers were added to culture 
media at a final concentration of 1 nM and incubated with 
live cells for 30 min in 37 °C in 5%  CO2. Following incu-
bation, cells were washed 3 × for 5 min each with PBS 
and fixed 10 min with 4% paraformaldehyde at RT. After 
fixation, cells were washed with PBS and counterstained 
with DAPI (Sigma), 1 µg final concentration for 5 min. 
To identify membrane co-localization of Cy3-Apt63 
and ATP5B antibody, cells were grown on coverslips in 
35 mm tissue culture dishes, and stained sequentially with 
Cy3-Apt63 and AlexaFluor®647 anti-ATP5B antibodies 
(ab223436, ABCAM), without a permeabilization step. To 
co-localize Apt63 and ATP5B antibody within mitochon-
dria, cells were treated with 0.05% Triton X-100 for 5 min, 
washed three times with PBS, then incubated with both the 
AlexaFluor®647 anti-ATP5B antibody and Cy3-Apt63. 
Finally, cells were counterstained with DAPI. For some 
experiments, live cells were first stained with Cy3-Apt63, 
followed by fixation, treatment with 0.05% Triton X-100, 
and DAPI counterstaining as described above. Coverslips 
were mounted with ProLong®Gold antifade reagent (Life 
Technologies). Fluorescent images were obtained on a 
confocal microscope (Leica SP5) using a 20x dry objec-
tive (Leica PL APO CS).
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Aptamer target purification and identification
Apt63 and scrambled sequence (AptScr) were 3′ end-bioti-
nylated using Pierce™ RNA 3′ End Desthiobiotinylation 
Kit (ThermoFisher Scientific, USA) following the manu-
facturer’s protocol. LNCaP-LN3 and LNCaP-Pro5 cells 
were each seeded into 100 mm Petri dishes for 48 h at 
a density 0.5 × 106 cells per dish and allowed to grow to 
60–75% confluency. On the day of the experiment, cells 
were incubated at RT for 1 h with the desthiobiotin-RNA-
Apt63 or -AptScr complexes, allowing aptamer to bind 
to target. Following binding, cells were washed 3 × for 
5 min each in PBS at RT to remove excess unbound RNA-
desthiobiotin complexes, and cross-linked by incubation 
with 1% paraformaldehyde for 2 min. Next, cells were 
thoroughly washed 3 × for 5 min each in PBS at RT. To 
separate membranes from intracellular components, cells 
were incubated in a mild hypotonic lysis buffer containing 
1 M Tris–HCl, 5M NaCl, 50 mM MgCl, 0.1M DTT, and 
protease inhibitor cocktail for 2 min on ice. Immediately 
following incubation, cells were gently homogenized in a 
Dounce homogenizer, ten times on ice, mixed with mag-
netic beads and left overnight at 4 °C to allow capture of 
the desthiobiotin-aptamer-target hybrid complexes. On the 
next day, the beads were thoroughly washed with reagents 
provided in the kit, and target-aptamer complexes eluted 
with 30 µL of 8M urea for 10 min at 60 °C. The recovered 
eluates and total cell lysate were separated on 4–20% gra-
dient SDS–PAGE gels (Bio-Rad, USA). Gels were stained 
using Pierce™ Silver Stain kits. Protein band distributions 
were compared between LNCaP-LN3 and LNCaP-Pro5 
cell lines, and the most enriched band in the LN3 aptamer-
target eluate was cut, sequenced by microcapillary LS/MS/
MS, and analyzed by SEQUEST software at Taplin Mass 
Spectrometry Facility (Harvard Medical School, Boston 
MA). The predicted protein target was verified by 4–20% 
gradient SDS-PAGE gel electrophoresis and western blot 
in whole cell lysates and aptamer eluates using ATP5B 
antibodies (ab170947, ABCAM) with ATP5B recombinant 
protein as a positive control (ab92235, ABCAM).
In vitro aptamer binding affinity and cytotoxicity 
assays
We used two independent methods to evaluate Apt63 
cytotoxicity in a series of cell lines in vitro: (1) direct 
visualization of Apt63 cytotoxicity using the IncuCyte® 
S3 Live-Cell Analysis System, and (2) SYTOX™ Green 
uptake. Binding affinity of Apt63 to its membrane target 
was measured using the CellTiter-Glo® system (Promega). 
Detailed procedures are described in Online Resource 2.
Mouse xenograft models and aptamer cytotoxicity 
in vivo
All animal experiments were approved by and performed in 
accordance with the guidelines of the University of Miami 
Institutional Animal Care and Use Committee. For live 
visualization of Apt63 tumor uptake and retention in vivo, 
a prostate xenograft tumor model was used. NOD.CB17-
Prkdcscid/J male mice (10 weeks old, n = 14, The Jackson 
Laboratory) were injected orthotopically into the right ante-
rior lobe of the prostate with 2 × 106 LN3 and 2 × 106 Pro5 
cells. For Apt63 cytotoxicity in vivo, we used a previously 
described breast tumor xenograft mouse model [24]. NOD.
CB17-Prkdcscid/J female mice (6–8 weeks old, n = 39, 
The Jackson Laboratory) were injected with  106 of MDA-
MB-231 cells into the mammary fat pad. In both xeno-
graft models, when tumors were palpable, 1 nmol of Alexa 
Fluor™ 647-labeled Apt63, AptScr, or unlabeled oligonu-
cleotides suspended in 200 µL of PBS was injected into the 
tail vein as a single injection. Mice were imaged and eutha-
nized at specified time points. Tumors and selected tissues 
were dissected and processed for further analysis. Detailed 
procedures are described in Online Resource 2.
Tumor tissue and FFPE human biopsy arrays 
fluorescent staining and analysis
Xenograft tumors were removed from euthanized mice and 
immediately frozen or fixed with 10% buffered formalin 
(VWR, USA), paraffin embedded, and processed. Prostate 
and breast core tissue microarrays (TMA) were purchased 
from US Biomax, Inc (Rockville, MD). The detailed staining 
protocols are provided in as described in Online Resource 
2. Cy3-Apt63-stained human breast biopsy microarrays 
were imaged by fluorescence microscopy on a Virtual Slide 
Microscope (VS120) for overview images and on a confo-
cal microscope (Leica SP5) for high-resolution images, and 
scored for visual presence or absence (greater or less than 
10% of cells, respectively) of Apt63 membrane-specific 
labeling. A list of TMAs with patient information, tumor 
grade, and stage used in this study and assigned Apt63 score 
for each biopsy is provided in Online Resource 3. Statistical 
analysis was performed for the Pearson correlation coeffi-
cient of aptamer membrane-specific stain vs. histopathologi-
cal grades and stages.
ATP5B expression datasets and analysis
ATP5B gene expression was analyzed in prostate and breast 
cancer samples downloaded from Gene Expression Omni-
bus and from the Genomic Data Commons Portal. Spe-
cifically, RNA-seq data in FPKM (Fragments Per Kilobase 
Million) and clinical information of the TCGA Prostate 
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Adenocarcinoma dataset (TCGA-PRAD [25]) were down-
loaded from the Genomic Data Commons Portal using 
functions of the TCGAbiolinks R package and used as is. 
Expression levels of prostate tumors (n = 264) and normal 
prostate tissue samples (n = 160) from Penney et al. [26] 
were downloaded from GEO GSE62872 as Series Matrix 
File and used as is. Raw data of 545 formalin-fixed paraffin-
embedded (FFPE) tissue samples from primary prostate 
cancer were downloaded from GEO GSE46691 [27]. Probe-
level signals were converted to expression values from CEL 
files using robust multi-array average procedure RMA [28] 
and an Entrez gene-centered custom CDF for Affymetrix 
Human Exon 1.0 ST Array (http://brain array .mbni.med.
umich .edu/Brain array /Datab ase/Custo mCDF/CDF_downl 
oad.asp; version 22). Gene expression profiles of 25 matched 
normal and tumor breast tissues were downloaded from 
GEO GSE109169 [29] as Series Matrix File and used as 
is. Full expression median-centered data, consisting of 522 
primary tumors, 3 metastatic tumors, and 22 tumor-adja-
cent normal samples, and clinical information of the TCGA 
Breast Invasive Carcinoma dataset (TCGA-BRCA;[30]) 
were downloaded from https ://tcga-data.nci.nih.gov/docs/
publi catio ns/brca_2012/ and used as is. Finally, we used a 
breast cancer compendium created from a collection of 4640 
samples from 27 major datasets containing microarray data 
on breast cancer samples annotated with clinical informa-
tion. The compendium consists of a meta-dataset of gene 
expression data for 3,661 unique samples from 25 independ-
ent cohorts [31, 32].
All data analyses were performed in R (version 3.5.1) 
using Bioconductor libraries (BioC 3.7) and R statistical 
packages. To identify two groups of tumors with either high 
or low ATP5B expression, we used the classifier described in 
[33], based on the standardized expression (score) of a gene 
or a signature. Tumors were classified as ATP5B ‘Low’ if 
the ATP5B score was negative and as ATP5B ‘High’ if the 
ATP5B score was positive. To evaluate the prognostic value 
of the ATP5B score, we used the Kaplan–Meier method to 
estimate the probability of metastasis-free survival. To con-
firm these findings, the Kaplan–Meier curves were com-
pared using the log-rank (Mantel–Cox) test. P-values were 
calculated according to the standard normal asymptotic dis-
tribution, using a cutoff of 0.05 for significance. Survival 
analysis was performed in GraphPad Prism.
Results
Identification of an aptamer recognizing aggressive 
cancer
As an initial approach to discovering features of cancers with 
high metastatic risk, we performed differential Cell-SELEX 
comparing two subclones of a single prostate cancer line 
(LNCaP) with divergent metastatic potential. Parental 
LNCaP and Pro5 variant lines, which are poorly metastatic, 
were used for library subtraction, while the aggressive LN3 
line was used for positive screening. 11 cycles of negative 
and positive selection were performed (Fig. 1a). Ongoing 
enrichment of high-affinity LN3-specific aptamers was 
monitored by SYBR® Green fluorescence as an indicator 
of annealing. Figure 1b shows RoT curve analyses at each 
cycle, demonstrating a progressive increase in binding affin-
ity and decreasing the complexity of aptamers as selection 
progress. Aptamer pools were sampled at cycles 0, 1, 4, and 
11 and sequenced. Sequences showing a frequency higher 
than 1/106 in the last analyzed cycle (i.e., cycle 11) were 
selected for further investigation. After this filtering step, 
691 unique sequences were clustered into families using 
Clustal Omega software [34] (Fig. 1c), and representative 
aptamers from each of 5 selected families were selected for 
further testing.
The selected RNA aptamers, together with scrambled 
controls, were labeled with Cy3 and incubated with live 
LN3 and Pro5 cells. Aptamers #63 and #41 showed strong 
binding to LN3, while only background fluorescence was 
seen with the other aptamers and control sequences (Fig. 1d 
and Online Resource 4). Pro5 cells were not bound by either 
aptamer or by scrambled controls (Fig.  1d and Online 
Resource 4). Because of the greater intensity of Apt63 fluo-
rescence, this sequence was chosen for further testing.
We next asked whether Apt63 would preferentially inter-
act with other highly metastatic cell lines derived from other 
tissues, including human prostate, human breast, and murine 
breast cancers. Non-tumorigenic and poorly metastatic cell 
lines were used for comparison (Fig. 2). As with LN3, the 
aggressive prostate cancer cell lines PC-3 and PC3-ML 
were strongly labeled by Apt63, while the non-tumorigenic 
prostate epithelial cell line RWPE-1 was not (Fig. 2a). The 
readily metastasizing MDA-MB-231 and MDA-MB-436 
breast cancer cell lines were also strongly labeled by Apt63, 
but the non-tumorigenic breast epithelial cell line MCF10A 
was not labeled, and the poorly metastasizing MCF-7 line 
was weakly bound by Apt63. The primary dissociated 
breast tumor line DT28, which metastasizes efficiently, 
was strongly labeled by Apt63, but the non-metastasizing 
DT22 line was not [35]. Apt63 also efficiently discriminated 
between murine breast cancer cell lines with different meta-
static potentials (Online Resource 5), indicating inter-species 
conservation of the binding target. Live cells stained with 
Apt63 showed a punctate pattern that appeared to be con-
centrated at the plasma membrane, with some variation in 
labeling intensity (Fig. 2a, b). These findings suggest that the 
target recognized by Apt63 is located on the cell surface and 
is a common feature among cell lines with high metastatic 
potential.
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Fig. 1  Identification of Aptamer 63 (Apt63) by differential Cell-
SELEX. a Schematic of the Cell-SELEX screening process (top). 
Representation of the RNA molecules library featuring a central 40 
random nucleotides (multicolor), flanked by forward (FP) and reverse 
(RP) primer sequences. The library was screened for differential bind-
ing to surface feature(s) unique to LNCaP-LN3 prostate cancer cells. 
Negative selection was performed using poorly metastatic LNCaP-
Pro5 cells (smooth black) and positive selection was performed on 
the highly metastasis-prone LN3 subclone (spiky red). Sequential 
negative and positive selection cycles enrich the aptamer pool for 
LN-binding sequences (top right). RNA aptamer pools were sampled 
after cycles 1, 4, and 11 and sequenced. Sequences enriched at cycle 
11 relative to earlier cycles were aligned and clustered (bottom right). 
b RoT curve analyses for cycles 0–11. Progressive increase in bind-
ing affinity is seen as the complexity of the aptamer pool decreases. 
Enrichment for high-affinity binding is detectable as early as cycle 
3. c Alignment of 5 sequences from (a) that was tested for selec-
tive in  vitro binding to LN3 cells. d The secondary structure of 2 
aptamer sequences showing selective binding to LN3 vs. Pro5 cells 
was determined using mFold Web Server (The RNA Institute, Uni-
versity at Albany, State University of New York). e Representative 
confocal images of LN3 and Pro5 cells bound by Cy3-labeled Apt63 
or AptScr. (Color figure online)
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Apt63 binding is selectively cytotoxic to cancer cells 
in culture and in vivo
We speculated that the target of Apt63 on LN3 cells might 
be functionally important in promoting its metastatic phe-
notype, possibly as a survival factor, and that binding by 
the aptamer might impair this function. Accordingly, we 
tested for direct Apt63 cytotoxicity in vitro, using two meth-
ods. First, real-time cytotoxicity was monitored in Apt63-
exposed LN3 cells by SYTOX® Green uptake and fluores-
cence, using an IncuCyte® S3 Live-Cell Analysis System. 
The SYTOX® Green nucleic acid dye is excluded by healthy 
cells with normal membrane permeability but diffuses pas-
sively through damaged membranes. After addition of Apt63 
or a scrambled aptamer (AptScr), together with SYTOX® 
Green, fluorescent images were recorded every 5 min for the 
duration of the experiment (Fig. 3a; see also the time-lapse 
video in Online Resource 6). No difference in cell death was 
seen among the various conditions at 20 min (Fig. 3a). By 
100 min, most LN3 cells exposed to Apt63 were brightly 
fluorescent, indicating cytotoxicity, but there was no change 
in ongoing basal death rates of Pro5 or AptScr-treated LN3 
cells (Fig. 3a). These findings suggest that Apt63 induces 
rapid cell death upon engagement of an LN3-enriched 
epitope, leading to membrane compromise and cell death 
within 2 h. Next, we estimated the dose dependence of Apt63 
cytotoxicity in LN3 cells using ATP content as an indicator 
of cell viability. Cells were exposed to a range of concen-
trations of Apt63 and media ATP fluorescence determined 
using a CellTiter-Glo® system as described in “Materials 
and methods.” A relatively sharp decrease in cell viability is 
observed at an approximate IC50 = 1.030 nM (R2 = 0.9497, 
Fig. 3b). For comparison, the IC50 for angiostatin in this 
assay was 1.66 µM (R2 = 0.884. Fig. 3b).
To determine whether Apt63 binding and cytotoxicity 
were correlated in other cell lines, we grew human PC3, 
PC3ML, RWPE, MDA-MB-231, MDA-MB-436, MCF7, 
MCF10A, and mouse T41 and NR 67 cell lines, along with 
Fig. 2  Discriminative staining of aggressive breast cancer by 
Aptamer 63. The indicated cancer cell lines in live in culture were 
incubated with 1  nmol of Cy3-labeled Apt63 (top) or a AptScr 
(below). a Aggressive PC-3 and PC-ML show positive staining by 
Apt63; prostate epithelial cell line RWPE does not show positive 
staining. b Weakly metastatic MCF-7, aggressive MDA-MB-231 and 
MDA-MB-436 breast cancer cell lines, and aggressive DT28 dis-
sociated tumor line show membrane-specific staining; a non-tumor-
forming breast epithelial cell line MCF10A and non-metastatic DT22 
tumor line do not have positive staining. Original confocal imaging 
magnification: × 20. (Color figure online)
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the original LN3 and Pro5 cell lines, in 96-well plates for 
24 h. Each cell line was treated with unlabeled 1 nM of Apt63 
and 5 nM SYTOX® Green dye for 3 h. Binding of Apt63 to 
live cells in culture correlated closely with rapid cytotoxic-
ity as shown by SYTOX® Green fluorescence (Fig. 3c, red 
bars; compare Fig. 2a). No cell death was seen with AptScr 
(blue bars). Non-tumorigenic epithelial cell lines RWPE and 
MCF10A, which do not bind Apt63, were completely resist-
ant, while cell lines with weak staining had correspondingly 
reduced susceptibility (e.g., MCF-7) (Fig. 3c). The residual 
toxicity of Apt63 in these weakly staining cells could reflect 
the presence of small subpopulations of vulnerable cells. 
Overall, however, these findings suggest that Apt63 cytotox-
icity is sequence-specific and dependent on the presence of a 
specific epitope found on multiple cancer cell types.
We then asked whether Apt63 could exert sequence-spe-
cific binding and toxicity for cells grown as xenograft tumors 
in vivo. In initial experiments, we tested whether LN3 and 
Pro5 tumor cells would differentially take up Apt63 after 
intravenous injection. Mice bearing LN3 and Pro5 xenograft 
tumors were injected with a single dose of 1 nmol of Alexa 
Fluor™ 647-labeled Apt63 or AptScr in 200 µL of PBS into 
the tail vein. Between 10 min and 3.5 h post injection, Apt63 
uptake could be detected in LN3 but not Pro5 xenografts 
in vivo (Fig. 3d) and in frozen sections of the same tumors 
(Fig. 3e). No Apt63 uptake was observed in Pro5 xenografts 
(Fig. 3d), suggesting that Apt63 selectively binds to and accu-
mulates in tumors expressing its plasma membrane target. 
We next injected Alexa  FluorTM-labeled Apt63 or AptScr into 
mice bearing MDA-MB-231 xenograft tumors in the mam-
mary fat pad. Mice were monitored and euthanized at 6, 24, 
and 48 h after a single tail vein injection of Apt63 or AptScr, 
and frozen sections of tumors were imaged as described 
above. The fluorescent label was retained by Apt63-exposed 
MDA-MB-231 xenografts for up to 48 h post injection, while 
only background AptScr signal was detectable at any point 
(Fig. 3f).
In the same images, we noted an increase in nuclear 
fragmentation in MDA-MB-231 xenografts by 24 h after 
injection of Apt63, relative to AptScr (Fig. 3f). We further 
explored this by electrophoresis of tumor DNA (Fig. 3g), 
which revealed a distinct nucleosomal DNA cleavage pattern 
in Apt63-treated tumors. The cleavage pattern resembled 
that produced by endonuclease G (endoG), a nuclease that 
is released from the inter-mitochondrial membrane space 
during oxidative stress and translocates to the nucleus to 
initiate a caspase-independent apoptotic pathway [36, 37]. 
Consistent with this, Apt63-treated MDA-MB-231 tumors 
showed considerable nuclear endoG staining by 24 h, while 
AptScr-treated tumors did not (Fig. 3h, arrowheads). These 
effects were not accompanied by any visible cytotoxicity 
toward adjacent non-tumor tissues, or any obvious adverse 
effects on the mouse overall conditions during the 48 h after 
injection. We interpret these results to show that Apt63 binds 
preferentially to breast and prostate tumor cells that express 
its plasma membrane target, and that Apt63 induces cell 
death upon binding, through a mechanism that involves 
release and nuclear translocation of endoG.
The target of Apt63 is the beta subunit of  F1Fo ATP 
synthase (ATP5B)
To obtain an enriched fraction of the aptamer target on LN3 
plasma membranes, we used a protocol combining a short 
detergent treatment with mild hypotonic lysis to segregate 
aptamer-bound membrane proteins from other cell compo-
nents (see “Materials and methods”). Electrophoresis of this 
fraction yielded a single predominant protein band (Fig. 4a, 
Fig. 3  Apt63 binding is selectively cytotoxic to cancer cells in cul-
ture and in vivo. a Rapid in vitro cytotoxicity induced by Apt63. Cell 
death was monitored in real time by SYTOX® Green fluorescence as 
described in “Materials and methods.” Representative photographs 
after 10  min (left column), and after 2-h post-treatment (right col-
umn). Original magnification: × 20. b Concentration dependence of 
Apt63 cytotoxicity. Apt63 (unlabeled) or angiostatin was added to 
the cells at the indicated concentrations and luciferin luminescence 
was measured at 2  h in an EnVision™ plate reader. Readings were 
normalized to untreated cells and plotted using GraphPad Prism 
8 Software. Apt63 IC50 = 1.030  nM. IC50 for angiostatin = 1.66 
micromolar (> 103 × higher). c Cell selectivity of Apt63 cytotoxicity. 
The indicated cell lines were incubated with Apt63 or a scrambled 
aptamer (AptScr) in the presence of SYTOX® Green. Y-axis indi-
cates absolute fluorescence units at 3 h. d, e Selective Apt63 uptake 
by LN3 xenograft tumors after intravenous injection in  vivo. LN3 
and Pro5 orthotopic tumor xenografts were established in mice as 
described in “Materials and methods,” and Alexa Fluor 647-labeled 
Apt63 or AptScr was injected via tail vein. d Representative in vivo 
images, 3.5  h post injection on an IVIS Spectrum in  vivo imaging 
system (Perkin Elmer). Arrows indicate the position of xenograft 
tumors in Apt63-injected mice; circle indicates site of a lung abscess 
identified postmortem. e. Selective uptake of Apt63 by LN3 cells. 
Frozen sections of tumors removed from animals 4  h after delivery 
of labeled aptamer were counterstained with DAPI. Representative 
fluorescence images are shown. f Apt63 binds to and induces nuclear 
fragmentation in MDA-MB-231 breast xenograft tumors in  vivo. 
Orthotopic MDA-MB-231 xenografts were established as described 
in “Materials and methods.” Mice received a single injection of 
1 nmol Apt63 by tail vein as in (d), above, and were euthanized 6, 
24, 48 h later. Xenograft frozen sections were prepared as in (e). Rep-
resentative images AptScr- (top) and Apt63- (center) labeled tumors 
at each time point. Note retention of fluorescent label and increased 
nuclear fragmentation in Apt63-exposed xenografts (arrowheads). 
(Bottom) Enlarged images showing DAPI-stained xenograft tumors 
at 48  h after injection of AptScr and Apt63. Arrows point to frag-
mented MDA-MB-231 nuclei in Apt63-exposed tumors. g Nucleo-
somal cleavage pattern in Apt63-treated cells. DNA fragmentation 
in Apt63-treated tumors was confirmed by electrophoresis of total 
genomic DNA. Electrophoresis of tumor DNA shows accumula-
tion of 300–400  bp DNA cleavage products (arrowheads). h Apt63 
induces EndoG translocation from mitochondria to nuclei. Xenograft 
frozen sections at 24  h were stained with rabbit polyclonal EndoG 
antibody (ab9647, ABCAM) and counterstained with DAPI. (Color 
figure online)
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Fig. 4  Identification of Apt63 target as cell surface  FoF1-ATP syn-
thase β-subunit ATP5B. a Apt63 associates with a 56kd protein in 
the LNCaP-LN3 plasma membrane. Representative SDS-PAGE 
gel of proteins immunoprecipitating with Apt63 from LN3 and 
Pro5 cell lines. Lane 1: LN3 whole cell lysate; Lane 2: LN3, mem-
brane-enriched fraction; Lane 3: Pro5 total cell lysate; Lane 4: Pro5 
membrane-enriched fraction. Equal amounts of protein were loaded 
in each lane. Bar at 56 kd indicates the predominant LN3 aptamer-
associated band subjected to mass spectroscopy as described in 
“Materials and methods” and Table 1. b Confirmation of  FoF1-ATP 
synthase β-subunit as aptamer target. Membrane fractions of LN3 and 
Pro5 prostate cells were separated as in (a). Plasma membrane-bound 
Apt63/target complexes (lanes 1–3), and whole cell lysates (lanes 
4–5) were obtained from indicated cell lines and immunoblotted with 
an anti-ATP5B monoclonal antibody. A single ~ 56 kd protein band 
co-migrating with recombinant ATP5B (lane 6) is present on the 
membranes of LN3 (lanes 1, 2) but not Pro5 cells (lane 3). Similar 
bands are present in whole cell lysates from both cell lines, reflecting 
the mitochondrial protein (lanes 4–5). c Apt63 co-localizes on plasma 
membrane with anti-ATP5B antibody. ATP5B antibody (green) and 
Apt63 (red) were bound to live LN3 cells, followed by fixation and 
imaging by confocal microscope. d The Apt63 target is extractable by 
detergent treatment of fixed cells. (left) Cy3-Apt63 (red) and plasma 
membrane marker WGA (green) were incubated with live cells fol-
lowed by fixation and imaging as in (c). (right) Similarly treated cells, 
except that fixed slides were subjected to a short 0.05% Triton X-100 
treatment. Note loss of Cy3 Apt63 signal from plasma membrane. e 
Apt63 stains mitochondria in permeabilized cells. Cells were fixed, 
then permeabilized with 0.05% Triton X-100 and incubated with 
Cy3-Apt63 or Cy3-AptScr and ATP5B antibody. In these permeabi-
lized LN3 cells, Apt63 and ATP5B antibody staining are co-localized 
within mitochondria. (Color figure online)
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lane 2.) A similar protein band was identified in PC-3 mem-
brane fractions (not shown). These bands were isolated and 
sent for protein sequencing by mass spectrometry (n = 2 
samples from LN3, n = 1 from PC3). The top hit in all 3 
samples was ATP5B, with 28.36% of the ATP5B protein 
sequence detected (Table 1).
To confirm the identity of the aptamer target, we per-
formed a western blot analysis of aptamer-associated cell 
membrane proteins and total cell lysates using an ATP5B 
antibody (Fig. 4b). A single protein band was present in 
Apt63-bound membrane fractions of LN3 (Fig. 4b, lanes 
1, 2) but not Pro5 cells (Fig. 4b, lane 3). The same band 
was readily detected in whole cell lysates of both cell lines 
(Fig. 4c, lanes 4, 5), and co-migrated with recombinant 
ATP5B protein (4c, lane 6). ATP5B antibody and Apt63 
co-localized on the surface of intact LN3 cells (Fig. 4d), and 
within mitochondria in permeabilized LN3 cells (Fig. 4e), 
consistent with ectopically expressed ATP5B on the plasma 
membrane as a common target of the antibody and Apt63. 
This surface target could be extracted by detergent treatment 
(Fig. 4d, right), further supporting the plasma membrane 
location of ATP5B.
Membrane ATP5B as a correlate of tumor metastasis 
in clinical populations
It is not clear how ATP5B gene expression and ecto-ATP5B 
levels are related in any given cell type; ATP5B protein is 
subject to substantial post-translational and functional regula-
tion, including plasma membrane redistribution [16, 38–41]. 
However, several components of the ATP synthase complex 
have been reported to be upregulated in cancer [40, 42, 43]. 
We therefore asked whether ATP5B expression was associated 
with cancer phenotypes in clinical populations by comparing 
ATP5B transcript levels in tumor vs. normal tissue in multiple 
prostate and breast cancer datasets. ATP5B expression was 
significantly higher in primary tumors when compared with 
normal tissues in both prostate (Fig. 5a–c) and invasive ductal 
breast cancer (Fig. 5d, e). In tandem with this, mean ATP copy 
number was significantly increased in ER-positive tumors, and 
in a subset of ER− (Fig. 5f), although interestingly the average 
copy number for ER− tumors was reduced. For both types of 
cancer, above-median ATP5B expression was associated with 
significantly decreased metastasis-free (Fig. 6a, b) and overall 
(Fig. 5c, d) survival. These findings are consistent with a role 
for ATP5B, along with other members of the complex, in sup-
porting metastatic progression.
To characterize ATP5B protein content in human breast and 
prostate cancer samples, we used Apt63 to label prostate and 
breast cancer tissue microarrays (TMAs) representing a range 
of tumor grades and stages. As in the xenograft studies shown 
above, we confirmed that Apt63 staining co-localized with 
staining by a monoclonal ATP5B antibody within tumor tis-
sue, while normal adjacent stroma was only minimally bound 
by either reagent (Fig. 7a). Both cytosolic and membrane 
staining patterns could be identified by high-resolution con-
focal microscopy. We observed considerable sample-to-sample 
heterogeneity of staining patterns across different categories of 
breast cancer; in some tumors, Apt63 predominantly labeled 
cytosolic components, including mitochondria, while in oth-
ers, a clear plasma membrane pattern was identified (Fig. 7b). 
Staining of normal tumor-adjacent tissue was consistently 
weak (Fig. 7b, brackets). Using a semi-quantitative score for 
the presence or absence of membrane-bound ATP5B (see 
Online Resource 2), we saw no consistent association between 
the presence of ecto-ATP5B and tumor grade, PAM50 sub-
type, or hormone receptor status. However, plasma membrane 
staining of breast cancer cells by Apt63 was strongly and posi-
tively associated with tumor stage (r = 0.997, p = 3.12E−03), 
appearing in 42/46 of lymph node metastases, 0/12 normal 
breast tissue samples, and intermediate values in DCIS and 
invasive carcinomas (summary is presented in Table 2 and in 
Table 1  Mass spectroscopy 
of membrane proteins 
immunoprecipitated from LN3 
and PC-3 by Apt63. Separate 
experiments and MS runs were 
performed for each cell line. 
The amino acid sequence of 
ATP5B is shown below with 
mapped peptides in italics
MLGFVGRVAA APASGALRRL TPSASLPPAQ LLLRAAPTAV HPVRDYAAQT SPSPKAGAAT 
GRI VAVIGAV VDVQFDEGLP PILNALEVQG RETRLVLEVA QHLGESTVRT IAMDGTEGLV 
RG Q KVLDSGA PIKIPVGPET LGRIMNVIGE PIDERGPIKT KQFAPIHAEA PEFMEMSVEQ 
EILVTGIKVV DLLAPYAKGG KIGLFGGAGV GKTVLIMELI NNVAKAHGGY SVFAGVGERT 
REGNDLYHEM IE SGVINLKD ATSKVALVYG QMNEPPGAR A RVALTGLTVA EYFRDQEGQD 
VLLFIDNIFR FTQA GSEVSA LLGRIPSAVG YQPTLATDMG TMQERITTTK KGSITSVQAI 
YVPADDLTDP APATTFAHLD ATTVLSRAIA ELGIYPAVDP LDSTSRIMDP NIVGSEHYDV 
ARGVQKILQD YKSLQDIIAI LGMDELSEED KLTVSRARKI QRFLSQPFQV AEVFTGHMGK 
LVPLKETIKG FQQILAGEYD HLPEQAFYMV GPIEEAVAKA DKLAEEHSS
Cell line Protein mass Amino acids Amino acids 
identified
Protein coverage 
(%)
Peptides 
identi-
fied
LN3 56524.61 529 118 AA 22.31 14
PC-3 56524.61 529 109 AA 20.60 13
Total 150 AA 28.36 27
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Online Resource 3). These results provide further support for 
a functional relationship between plasma membrane ATP5B, 
as indicated by binding by Apt63, and breast cancer metastasis.
Discussion
Here we show that ectopic plasma membrane ATP5B, a sub-
unit of  F1Fo-ATP synthase, denotes a high metastasis-risk 
phenotype in breast and prostate cancer, and a vulnerability 
of cancer cells in vivo.  F1Fo ATP synthase is a highly con-
served enzyme complex residing on the inner mitochondrial 
membrane, where it conducts the final step in oxidative ATP 
production. Its 30 protein components are organized into 
two domains, the  Fo proton-translocating domain and the  F1 
catalytic domain [44, 45]. Three pairs of ATP5A and ATP5B 
subunits form the catalytic core of  F1 in the inner mitochon-
drial membrane, generating ATP molecules as H + transits 
the  Fo pore. Defects in ATP synthase contribute to diseases 
including microbial infection, immune deficiency, neuropa-
thies, obesity, diabetes, and cancer [35, 46, 47].
A plasma membrane-located ATP synthase (ecto-ATP 
synthase) was initially discovered as a cancer neoantigen 
more than 20 years ago [48]. Fully functional ATP synthase 
complexes have been identified on the plasma membrane 
of certain normal and many tumor cells, and may either 
Fig. 5  ATP5B expression is 
increased in prostate and breast 
cancer vs. normal tissue. Data-
sets were reviewed as described 
in “Materials and methods.” 
a ATP5B expression is 
increased in prostate adenocar-
cinoma compared with normal 
prostate tissue (p = 3.54e−4). 
GS = Gleason stage. Data from 
Vanaja et al. [74]. b ATP5B 
overexpression in GSE62872 
prostate samples compared with 
normal prostate tissues (n = 424; 
p-value < 0.0001). c ATP5B 
overexpression in TCGA-
PRAD samples compared 
with normal prostate tissues 
(n = 551; p-value = 0.0001). 
d ATP5B overexpression in 
GSE109169 breast cancers 
compared with their paired 
normal breast counterparts 
(n = 50; p-value = 0.0004). 
Gray lines link normal and 
tumor paired samples. e ATP5B 
overexpression in breast ductal 
cancers as compared to normal 
mammary tissues (n = 544; 
p-value = 0.0005). Data 
obtained from TCGA-BRCA 
database. f ATP5B copy num-
ber variation in breast cancer 
compared to normal blood cells. 
Copy number is significantly 
increased in ER + tumors. Data 
from TCGA Breast 2 dataset. 
(Color figure online)
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hydrolyze or synthesize ATP [10, 11]. Ecto-ATP synthase 
has been proposed to act as a receptor for apo-A1 and 
thereby to regulate HDL uptake by hepatocytes [49, 50] 
and to promote endothelial progenitor cell proliferation and 
angiogenesis [51]. Angiostatin has been shown to bind to 
ecto-ATP synthase and disrupt its ATP synthetic activity, 
contributing to its anti-angiogenic effects [10, 52]. How-
ever, angiostatin is able to exert these functions through 
other receptors on the cell surface, including c-met [53], 
proteoglycan NG2 [54], and annexin II [55]. The importance 
of these functions of ecto-ATP synthase in normal cells 
remains to be fully elucidated [38, 56].
ATP5B emerged in our unbiased screen as a plasma 
membrane feature that distinguishes the aggressive 
LNCaP-LN3 cell line from isogenic LNCaP and LNCaP-
Pro5 cells, which metastasize infrequently [19]. Collec-
tively, our data suggest that acquiring this feature may 
have enabled the metastatic phenotype of the LN3 sub-
clone. Despite substantial effort, no other specific driv-
ers of the aggressive LN3 phenotype have been identified. 
LN3 cells grow well in the absence of androgen, but do 
no evidence metastasis
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Fig. 6  Increased ATP5B expression is associated with greater risk of 
metastasis and reduced overall survival in prostate and breast cancer. 
a ATP5B expression is increased in primary prostate tumors that later 
metastasize. Primary prostate cancers with metastatic disease pro-
gression were compared to samples with no evidence of metastasis. 
Data were obtained from GSE46691 [27] (n = 545; p-value = 0.0063). 
b High expression of ATP5B mRNA correlates with decreased over-
all survival in prostate cancer patients of the TCGA-PRAD dataset 
(n = 551). Patients with high and low ATP5B expression are shown 
in red and blue, respectively (see “Materials and methods”). Patients 
with high expression (n = 250) had lower overall survival probability 
over time (log rank p-value = 0.050). c High expression of ATP5B 
mRNA correlates with reduced metastasis-free survival in patients of 
a compendium of 3661 breast cancer samples. Patients with high and 
low ATP5B expression are shown in red and blue, respectively (see 
“Materials and methods”). Patients with high expression (n = 1656) 
had higher probability to develop metastasis over time (log rank 
p-value = 0.0039). d High expression of ATP5B mRNA correlates 
with poor overall survival in breast cancer patients of the TCGA-
BRCA dataset (n = 522). Patients with high and low ATP5B expres-
sion are shown in red and blue, respectively (see “Materials and 
methods”). Patients with high expression (n = 263) had lower overall 
survival probability over time (log rank p-value = 0.0198). (Color fig-
ure online)
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not have androgen receptor amplification [57]; LN3 also 
exhibits higher resistance to apoptosis, associated with up-
regulation of anti-apoptotic BCL-2 and down-regulation of 
BAK and BAX [57]. LN3s express higher levels of mac-
rophage-inhibitory cytokine-1 (MIC1/GDF15) [58], the 
chaperone gp96 [59] and VEGFA [60], and have greater 
tumor vascularity [59, 60] than non-metastatic LNCaP 
lines. No genetic differences have been shown to explain 
these properties, although LN3 displays unique deletions 
in 16q23–qter and 21q of unknown functional significance 
[61] and lacks a missense mutation in PlexinB1 found 
in parental LNCaP cells that appears to be silent [62]. 
Fig. 7  Apt63 binds to a subset of aggressive breast tumors and co-
localizes with ATP5B. a Primary tumor core biopsies (top row) 
and adjacent normal tissue (bottom row) with anti-ATP5B (Abcam 
#14730) using HRP (far left) or Alexa Fluor® 647 ATP5B antibodies 
(ab223436, ABCAM) (near left). ATP5B (assigned green color) and 
Cy3-Apt63 (red color) extensively co-localize both at cell membranes 
and in the cytosol. b Heterogeneous binding of Cy3-Apt63 to primary 
breast tumors and lymph node metastases. Brackets indicate normal 
adjacent tissues in the top row. c–f Representative high-resolution 
confocal images of normal tissue (c), ductal carcinoma in situ (DCIS) 
(d), invasive ductal carcinoma (CA) (e), and lymph node metastases 
(LN) (f), imaged with Cy3-Apt63. A membrane staining pattern, as 
well as cytosolic staining, can be seen in (e) and (f). Original magnifi-
cation: x20. Results shown are representative of findings in a total of 
417 breast biopsies. (Color figure online)
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Previous proteomic analyses found no features distin-
guishing LN3 from the less-aggressive isogenic lines [63]. 
The same study found that endoplasmic reticulum pro-
tein ERp5 is overexpressed and displayed on the plasma 
membrane of both LN3 and Pro5 cells, demonstrating that 
cycling of intracellular peptides to the plasma membrane 
is not a rare event during tumorigenesis [63].
Considerable evidence links ecto-ATP synthase to aggres-
sive cancer cell growth. Plasma membrane-associated ATP5 
subunits, including ATP5B, have been correlated with more-
aggressive, larger and more advanced tumors, in multiple 
cancers including breast, lung, and prostate [17, 42, 64]. In 
our breast cancer TMA analysis of Apt63 binding, including 
biopsies representing 416 subjects, surface ATP5B appears 
to define a unique subset of highly aggressive breast and 
prostate cancers, present on 45% of DCIS and 55% of inva-
sive ductal carcinomas, and on almost all (91.3%) lymph 
node metastases. Apt63 staining did not appear to align with 
tumor size or hormone receptor status, suggesting that ecto-
ATP5B denotes an independent tumor phenotype. Surface 
ATP5B also appears to be important as a tumor-specific 
survival factor: cancer cells expressing ecto-ATP5B were 
rapidly killed by Apt63 binding, undergoing nuclear trans-
location of endonuclease G and DNA fragmentation, while 
adjacent normal tissues were spared. This selective toxic-
ity could mean that certain breast and prostate tumors are 
dependent on the presence of functional ecto-ATP synthase, 
and points to a vulnerability not shared by non-transformed 
cells.
The biological importance of ecto-ATPase has been 
explored using a range of physiological and synthetic 
ligands, including angiostatin, plasminogen, monoclonal 
antibodies, peptides, and small molecules binding to the  F1 
module [12, 14, 16, 64–67]. The effects of these agents are 
both cell type and ligand-specific, but most reduce extracel-
lular ATP production and cell proliferation, and some initiate 
programmed death. In HUVECs, which express high levels 
of ecto-ATP synthase, angiostatin inhibited cell proliferation 
and ATP production, but was not cytotoxic [10]; in A549 
lung cancer cells, both angiostatin and a polyclonal anti-
ATP5B antibody blocked ATP synthesis, induced intracel-
lular acidification, and triggered cell death [68]. A mono-
clonal ATP5B antibody (McAb178-5G10) inhibited surface 
ATP generation and inhibited proliferation of HUVECs and 
MDA-MB-231 cells, but was not toxic by itself [69]. The 
same antibody induced apoptosis in A549 cells, accompa-
nied by falls in extracellular ATP, intracellular pH, and ERK 
and AKT phosphorylation [14]. Another monoclonal anti-
body against ATP5B (mAb6F2C4) inhibited extracellular 
ATP synthesis, proliferation, anchorage-independent colony 
formation of the hepatoma cell line SMMC-7721 [65]; this 
antibody was also able to reduce hepatoma xenograft growth 
in vivo. The kringle 1–5 domain of plasminogen, an ecto-
ATP synthase ligand, triggered caspase-dependent apop-
tosis in endothelial cells [52]. On the other hand, binding 
of apolipoprotein A1 to ecto-ATP synthase promoted the 
survival and differentiation of endothelial progenitor cells 
[51]. Differences in binding sites, effects on enzyme con-
formation, and protein interactions of ATP synthase ligands 
could explain these divergent effects. Additional microen-
vironmental factors, including acidic extracellular pH, may 
permit tumor-selective killing [13, 65]. Further studies will 
be required to elucidate the specific mechanisms of Apt63-
induced programmed cell death in breast and prostate can-
cer, including effects on extracellular pH, reactive oxygen 
species, and purinergic nucleotides.
The quantitative relationship between ATP5B gene expres-
sion and surface ATP synthase is undetermined and likely 
complex: ATP synthase subunits are encoded by both nuclear 
and mitochondrial genomes, and are coordinately regulated 
through incompletely defined translational and post-transla-
tional means [38, 39, 41, 70–72]. Nonetheless, the associations 
we have identified between ATP5B gene expression and both 
metastasis-free and overall survival in breast and prostate can-
cer are remarkable. It is possible that proteomic analysis would 
demonstrate still stronger links. Comparing the proteomes of 
Table 2  Tissue biopsies by 
pathology groups and scoring 
for Apt63 membrane staining
High-resolution confocal images of Cy3-Apt63 TMAs were examined for membrane-pattern staining as 
illustrated in Fig. 7. Apt63-specific membrane staining correlates with cancer stage, r = 0.997 and p-value 
3.12E-03(*carcinoma). Group of benign tumors represented by adenosis, hyperplasia, and fibroadenosis. 
Online Resource 3 contains the complete list of 416 core biopsies with stage, grade, pathology diagnosis, 
and Apt63 score
Tissue Apt63 positive Total samples Percent (%)
Normal breast tissue 0 12 0.00
Benign tumors 4 31 12.90
Cancer-adjacent normal breast tissue 3 19 15.79
Breast Invasive lobular CA* 11 30 36.67
Ductal CA* in situ 10 22 45.45
Breast invasive ductal CA* 109 198 55.05
Lymph node metastases 42 46 91.30
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MCF-7 breast cancer and a highly invasive subclone, Pan 
et al. [42] found that another ATP synthase subunit, ATP5A 
was overexpressed in the aggressive subclone. ATP5A was 
identified on the surface of these cells, as well as on MDA-
MB-231 and MDA-MB-453 breast cancer cell lines, but not 
on parental MCF-7 cells, or on non-tumorigenic MCF-10F 
breast epithelial cells [42]. In parallel, increased immunoreac-
tive ATP5A was seen in 94% of breast cancers, as well as in 
21.2% of normal tissues. This analysis did not discriminate 
between membrane and cytosolic staining, but the findings 
are consistent with a relationship between ATP5 protein levels 
and appearance on the plasma membrane. Other investigators 
have shown that ATP5B and other subunits of ATP synthase 
travel on lipid rafts that may shuttle between mitochondrial and 
plasma membranes [16, 73]; co-localization with caveolin-1 
may be required to maintain a functional surface complex in 
vascular endothelium [73]. It will be important to examine 
the extent to which ATP5B expression correlates with surface 
ATP5B in future clinical studies of breast cancer prognosis.
A challenge in determining whether and how cancer cells 
utilize ecto-ATP synthase lies in the essential role of this 
enzyme in normal cell metabolism, and the unclear pathway 
by which the complex arrives at the cell surface. Our aptamer 
represents a new tool that will assist in elucidating these ques-
tions. Its rapid and selective cytotoxicity to cells expressing 
ecto-ATP5B may help to resolve structural and mechanistic 
questions about the importance of this complex to cancer cell 
survival and metastasis. Ultimately, the ability of Apt63 ability 
to target this important but poorly understood tumor antigen in 
primary breast and prostate tumors may help both to predict 
and mitigate the risk of future metastasis.
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